Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Talha Badar

Showing results (61-70 of 113) with videos related to

Pageof 12
Sort By:
Bone Marrow Transplantation|April 7, 2021
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world dataTalha Badar, Aniko Szabo, Mark Litzow, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.
American Journal of Hematology|September 10, 2024
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional studyTalha Badar, Ravi Narra, Alice S Mims, et al.
Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
Blood Advances|May 27, 2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomabTalha Badar, Aniko Szabo, Anjali Advani, et al.
Haematologica|July 17, 2025
Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatmentOudai Alkabbani, Yazan Jabban, Rong He, et al.
American Journal of Hematology|February 18, 2026
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating AgentNaseema Gangat, Momna Warraich, Sudhesh Kumar, et al.
British Journal of Haematology|December 12, 2023
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)Ayalew Tefferi, Farah Fleti, Onyee Chan, et al.
American Journal of Hematology|January 28, 2025
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic RelevanceAyalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, et al.
Pageof 12

Showing results (61-70 of 113) with videos related to

Sort By:
Pageof 12
Bone Marrow Transplantation|April 7, 2021
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world dataTalha Badar, Aniko Szabo, Mark Litzow, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.
American Journal of Hematology|September 10, 2024
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional studyTalha Badar, Ravi Narra, Alice S Mims, et al.
Cancer|December 22, 2022
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemiaTalha Badar, Mark R Litzow, Rory M Shallis, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
Blood Advances|May 27, 2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomabTalha Badar, Aniko Szabo, Anjali Advani, et al.
Haematologica|July 17, 2025
Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatmentOudai Alkabbani, Yazan Jabban, Rong He, et al.
American Journal of Hematology|February 18, 2026
TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating AgentNaseema Gangat, Momna Warraich, Sudhesh Kumar, et al.
British Journal of Haematology|December 12, 2023
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)Ayalew Tefferi, Farah Fleti, Onyee Chan, et al.
American Journal of Hematology|January 28, 2025
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic RelevanceAyalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, et al.
Pageof 12